enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up - AOL

    www.aol.com/news/ionis-ions-q3-earnings-sales...

    For premium support please call: 800-290-4726 more ways to reach us

  3. Ionis (IONS) Q3 Earnings & Revenues Fall Short of Estimates - AOL

    www.aol.com/news/ionis-ions-q3-earnings-revenues...

    For premium support please call: 800-290-4726 more ways to reach us

  4. Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL

  5. Stock market today: Nvidia and other tech stocks drive Wall Street higher. U.S. stock indexes are rising Monday to recover more of the holiday-season slide that bridged the new year. The S&P 500 was 1.3% higher in midday trading and on track for a se…

  6. Stock market news live updates: Stocks rebound to close ... - AOL

    www.aol.com/finance/stock-market-news-live...

    “If your stock rallies on bad news, that’s a pretty good sign the markets have absorbed and digested and have priced in the bad news.” 4:12 p.m. ET: Netflix reports subscriber loss for first ...

  7. Ionis Pharmaceuticals (IONS) Q3 Earnings and Revenues Beat ...

    www.aol.com/news/ionis-pharmaceuticals-ions-q3...

    Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 158.06% and 11.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for ...

  8. Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.

  9. Ionis Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Ionis_Pharmaceuticals

    Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.The company has three commercially approved medicines: Spinraza (), Tegsedi (), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA ...